Anthony @ Equity Investigations, Dear Anthony, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony,

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Anthony@Pacific who wrote (10733)	2/11/1999 4:19:00 PM
From: Doorman	Read Replies (1) of 122088

To clarify -- Bristol Myers said "no confidence" regarding Angiostatin - one of two closely related ENMD angiogenesis inhibitors that have been the topic of much hype and speculation as potential cancer breakthrough drugs. The article in the Boston Globe has to do with Endostatin - the other angiogenesis inhibitor ENMD has in the pre-clinic. The National Cancer Institute is sponsoring the research for Endostatin and the article says that after failing in their own lab to duplicate ENMD's data, the NIC was finally able to duplicate the results when they did it at ENMD's facility. They now will attempt to reproduce once more at their own lab. Even if they do - we're talking mice!! It's a long shot to expect it to succeed through the rigors of human clinicals and several years away from commercialization in a best case scenario. P.S. On another topic, what caused you to cover IMON?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next